Pathology: metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA); metastatic/advanced RCC (mRCC) - 1st line (L1); mRCC - L1 - PDL1 positive;
| metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) | metastatic/advanced RCC (mRCC) - 1st line (L1) | mRCC - L1 - PDL1 positive | ||
| IMmotion-010, 2017 | IMmotion-150 (At - all population), 2018 | IMmotion-150 (At - PDL1>1%), 2018 | ||
| atezolizumab alone | 3 | T1 | T1 | T1 |
| sunitinib | 0 | T0 | T0 | |
| placebo | 0 | T0 |